Regulation & Compliance

Teamsters' national president and CA's Lt. Governor join striking CSU workers, accusing the university of unlawfully withholding contractually promised raises.

As deepfakes and synthetic identities surge, Aware, Inc. earns critical third-party certifications, proving its tech is secure, fair, and ready for reality.

Online casino Betty expands its Toronto footprint with new TFC and Argos partnerships, navigating a market defined by rapid growth and strict regulations.

Cyrano Therapeutics' CYR-064 shows promise in a Phase 2 study, potentially becoming the first approved drug for persistent post-viral smell loss.

Nakamoto Inc. acquires Bitcoin Magazine's parent and a key investment firm in an all-stock deal, raising questions about market influence and shareholder value.

A partial DHS shutdown deepens as Democrats demand major reforms to ICE operations, sparking a fierce debate over national security and civil liberties.

New research reveals a startling mobile security gap, with 72% of firms facing incidents and 65% losing customers as AI and speed pressures add new risks.

Lufax names Xiang Ji as its new CEO amid major financial struggles. The move signals a tighter grip from controlling shareholder Ping An Group.

A new network of local recycling facilities aims to solve the e-waste gap for small businesses, boosting data security and domestic materials recovery.

Neurotech leader BrainsWay adjusts its share structure in a move to enhance liquidity, clarify valuation, and attract a broader base of global investors.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

As Xtract One readies its Q2 results, investors eye its booming backlog against a backdrop of rising competition and ethical questions in AI security.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

Zefiro Methane founder accuses the board of entrenchment tactics, setting the stage for a critical BCSC hearing that will shape the company's future.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

Landmark Phase 3 trial results show psilocybin offers rapid, lasting relief for severe depression, pushing psychedelic medicine closer to the mainstream.

As BRC Inc. preps its 2025 earnings report, can its new energy drink line and veteran mission overcome inflation, lawsuits, and declining margins?

With a new $12M investment, Lightworks aims to help large firms move AI from pilot to production by solving the critical challenges of safety and compliance.

A Swedish biotech and Belgian university secure major EU funding to advance a first-in-class drug against glioblastoma, a notoriously deadly brain tumor.